Drug intelligence / Profile preview

NL201

Development stage: Phase 3
Lead developer: Northland Biotech
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

NL201 is a genetically modified recombinant human interleukin-11 (mIL-11) being developed by Beijing Northland Biotech for the prevention and treatment of chemotherapy-induced thrombocytopenia (CIT) in cancer patients. As a cytokine therapy, it acts as an agonist for the interleukin-11 receptor complex, stimulating the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, thereby increasing platelet production. NL201 is a modified version of recombinant human interleukin-11 (rhIL-11), designed to optimize efficacy and safety. It is currently undergoing Phase 3 clinical evaluation as a subcutaneous injection to manage low platelet counts resulting from cancer chemotherapy.

Other names: genetically modified recombinant human interleukin-11modified recombinant human interleukin-11

Targets

IL6ST (Interleukin-6 receptor subunit beta)IL11RA (Interleukin-11 receptor subunit alpha)

Beyond the preview

Go deeper on NL201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NL201.

Explore the full profile